7 Stocks Likely to Move Big on Mental/Neurological Disease Readouts 📈 📉
With the year coming to a close, some stocks likely to move big in Q4 are yet to readout.
See table below for 7 of the anticipated mental/neurological disease readouts happening in Q4 '24 to Q1 '25 👇
$ATAI ✔️
ELE-101 / Major Depressive Disorder (MDD) / Phase 2a
» Well-tolerated with no serious or severe adverse events (AE)
» Dose-proportional PK profile: inter-subject variability compared to oral psilocybin
» Potential treatment time of ~two hours in the clinic
Prior results & Ph2a trial overview 📸 👇
$AXSM ✔️
AXS-05 / Alzheimer's Disease (AD) Agitation / Phase 3
» Rapid, substantial, and statistically significant improvements in CMAI total score versus placebo
» Statistically superior to bupropion at Week 5
» Almost 50% reduction from baseline in agitation symptoms
See Ph2/3 trial results below 📸
$IKT
Risvodetinib (IkT-148009) / Alzheimer's Disease (AD) Agitation / Phase 2
» The '201' trial is a 1:1:1:1 randomized, double-blind, twelve-week dosing trial
» Three randomized doses: 50, 100 or 200 mg given once daily, or to a placebo dose
» Phase 1/1b '101' study terminated early; demonstrated favorable safety, tolerability, and pharmacokinetic profile in single doses up to 325 mg and multiple doses up to 100 mg
Trial overview and early observations 📸
$NMRA ✔️
Navacaprant (NMRA-140) / Major Depressive Disorder (MDD) / Phase 3
» Robust Ph2 data in moderate to severe patients
» First program to demonstrate improvement in both symptoms of Depressed Mood and Anhedonia
» Well-tolerated & not associated w/ weight gain or sexual dysfunction
Ph2 trial results and Ph3 KOASTAL study overview 📸
$GHRS ✔️
GH001 (inhalable mebufotenin) / Treatment-resistant Depression (TRD) / Phase 2b
» Ph1/2 showed 87.5% (7/8) patients achieved remission by Day 7
» Mean change from baseline in MADRS score was -24.4 at day 7
» Well tolerated across completed trials with no severe or serious AEs
Ph1/2 trial results and Ph2b trial overview 📸
$AVXL
ANAVEX 2-73 (Blarcamesine) / Alzheimer’s Disease / Phase 2b/3
» Initial data demonstrate pre-specified clinical efficacy through upstream SIGMAR1 activation
» TEAEs tend to occur in first 24 weeks and related to titration schedule
Ph2b/3 trial overview and initial data 📸
$SUPN
SPN-830 (apomorphine infusion device) / Parkinson’s Disease / PDUFA
» Ph3 demonstrated 2.47hrs/day reduction in OFF time compared to placebo (0.58)
See Ph3 trial results below 📸
See table below for upcoming Big Movers on Mental/Neurological Disease Readouts
in Q4 '24 to Q1 '25 📈 📉
⏰ Limited Time Offer (Ends on 12/30):
Become a BPIQ Elite member with our Holiday Sale (50% Off) 🎄
✨ BPIQ Elite member gets...
🗓 All catalyst & PDUFA dates!
🚀 Big/Suspected Movers
🐳 Hedge fund analysis & M&A data!
📈 Stock ideas from our model portfolio!
🔐 Lock in the discount with a free trial!
#ATAI #AXSM #IKT #NMRA #GHRS #AVXL #SUPN
This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.
Article history:
First published 12/27/24 EJV, JD, AV